Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
TRIAZOLAM TABLETS | Assay | USP35–NF30 | 4936 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 2: Change Mobile phase and Chromatographic system—Proceed as directed in the Assay under Triazolam. to: Mobile phase—Prepare a filtered and degassed mixture of acetonitrile, chloroform, butyl alcohol, water, and glacial acetic acid (850:80:50:20:0.5… Read More |
VINCRISTINE SULFATE | IMPURITIES/Organic Impurities | USP35–NF30 | 5022 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 5 of Analysis: Change Result = [rUA/(ΣrUA + 25rUB)] × 100 to: Result = [rUA/(ΣrUA + 30rUB)] × 100 AND Change line 12 of… Read More |
ZINC GLUCONATE | IMPURITIES/Limit of Cadmium | USP35–NF30 | 5070 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 22 of Analysis: Change W = weight of Calcium Gluconate taken to prepare Sample solution A (g) to: W = weight of Zinc Gluconate taken to prepare Sample solution A (g) |
ALLANTOIN | IDENTIFICATION | First Supplement to USP35–NF30 | 5429 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of B. Thin-Layer Chromatographic Identification Test <201>: Change The RF value of the principal spot from Sample solution A corresponds to that from Standard solution A, as described in the test for Organic Impurities. to: The… Read More |
<232> ELEMENTAL IMPURITIES--LIMITS | Drug Products/Large Volume Parenterals | Second Supplement to USP35–NF30 | 5633 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Row 16 of Column 4 of Table 1: Change 70 to: 100 AND Row 16 of Column 5 of Table 1: Change 25 to: 10 |
AZITHROMYCIN FOR INJECTION | IMPURITIES/Limit of Aminoazithromycin, Formamido Analog, Methylformamido Analog, and 3’-De(dimethylamino)-3’-oxoazithromycin (if present) | Second Supplement to USP35–NF30 | 5910 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of Buffer: Change 3.5 g/mL to: 3.5 g/L |
ADAPALENE | IMPURITIES/Residual Solvent: Limit of Triethylamine | Revision Bulletin (Official December 01, 2012) | Online | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of Diluent: Change Dimethyl sulfoxide and 1 N sodium hydroxide solution (4:1) to: Dimethyl sulfoxide AND Line 1 of Standard solution: Change 3.2 μg/mL of USP Triethylamine RS in Diluent to: 4.0 μg/mL of USP Triethylamine RS in Diluent.… Read More |
TACROLIMUS ORAL SUSPENSION | ASSAY/Chromatographic system | USP36–NF31 | 5261 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | After line 1 of Column: Add a new section Column temperature: 70° |
CAPTOPRIL ORAL SUSPENSION | Assay | USP35–NF30 | 2477 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of Mobile phase: Change Prepare a filtered and degassed mixture of methanol and water (11:9) containing 0.5 mL of phosphoric acid. to: Methanol and water (55:45) containing 0.5 mL/L of phosphoric acid. Filter, and degas. |
<232> ELEMENTAL IMPURITIES--LIMITS | Drug Substance and Excipients | Second Supplement to USP35–NF30 | 5633 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Row 16 of Column 4 of Table 2: Change 7 to: 10 |
Olanzapine Tablets | ASSAY/Procedure | Revision Bulletin (Official July 01, 2012) | Online | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 10 of Analysis: Change CU = concentration of olanzapine in the Sample solution (mg/mL) to: CU = nominal concentration of olanzapine in the Sample solution (mg/mL) |
Olanzapine Tablets | IMPURITIES/Organic Impurities | Revision Bulletin (Official July 01, 2012) | Online | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 11 of Analysis: Change CU = concentration of olanzapine in the Sample solution (mg/mL) to: CU = nominal concentration of olanzapine in the Sample solution (mg/mL) |
Olanzapine Tablets | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Revision Bulletin (Official July 01, 2012) | Online | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Lines 3 and 6: Change USP Olanzapine Related Compound A RS 5-Methyl-2-((2-nitrophenyl)amino)-3-thiophenecarbonitrile. USP Olanzapine Related Compound B RS 2-Methyl-10H-thieno-[2,3-b][1,5]benzodiazepin-4[5H]-one. to: USP Olanzapine Related Compound A RS 5… Read More |
<81> Antibiotics—Microbial Assays | Turbidimetric Method | USP35–NF30 | 74 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 8 of Analysis: Change Include in each rack 1–2 control tubes containing 1 mL of the inoculum medium (see Table 8) but no antibiotic. to: Include in each rack 1–2 control tubes containing 1 mL of the test diluent (see Table 7) but no antibiotic. |
Polysorbate 80 | SPECIFIC TESTS/Fats and Fixed Oils, Hydroxyl Value <401> | USP35–NF30 | 1920 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 13 of Analysis: Change 0.5 N alcoholic potassium hydroxide to: 0.5 N alcoholic potassium hydroxide VS |
Polysorbate 80 | SPECIFIC TESTS/Fats and Fixed Oils, Peroxide Value <401> | USP35–NF30 | 1920 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 5 of Analysis: Change 0.01 M sodium thiosulfate to: 0.01 M sodium thiosulfate VS |
Polysorbate 80 | SPECIFIC TESTS/Fats and Fixed Oils, Saponification Value <401> | USP35–NF30 | 1920 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 3 of Analysis: Change 0.5 N alcoholic potassium hydroxide to: 0.5 N alcoholic potassium hydroxide VS Line 6 of Analysis: Change 0.5 N hydrochloric acid to: 0.5 N hydrochloric acid VS |
Aminosalicylate Sodium | Limit of m-aminophenol | USP35–NF30 | 2177 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of Test preparation: Change Use the Assay preparation, prepared as directed in the Assay. to: Transfer about 69 mg of Aminosalicylate Sodium, accurately weighed, to a 100-mL low-actinic volumetric flask, add 50 mL of Mobile phase, and swirl to dissolve.… Read More |
Aminosalicylate Sodium Tablets | Limit of m-aminophenol | USP35–NF30 | 2178 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of Test solution: Change Use the Assay preparation, prepared as directed in the Assay. to: Weigh and finely powder not fewer than 20 Tablets. Transfer an accurately weighed portion of the powder, equivalent to about 690 mg of aminosalicylate sodium, to a 100-mL… Read More |
Aminosalicylic Acid Tablets | Limit of m-aminophenol | USP35–NF30 | 2179 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Change the subsection: Mobile phase and Internal standard solution—Prepare as directed in the Assay under Aminosalicylic Acid. to: Mobile phase—Prepare as directed in the Assay under Aminosalicylic Acid. Internal standard solution… Read More |
Ampicillin Sodium | SPECIFIC TESTS/pH <791> | USP35–NF30 | 2213 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 2: Change text of Sample solution from 10.0 mg/mL to: 10.0 mg/mL of ampicillin |
Budesonide | ASSAY/Procedure | USP35–NF30 | 2394 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 2 of Acceptance criteria: Change Epimer A: 40.0%–51.0% on the dried basis to: Epimer A: 40.0%–51.0% |
Dibasic Calcium Phosphate Dihydrate | ASSAY | USP35–NF30 | 2463 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 14 of Analysis: Change W = Sample weight (mg) to: W = Sample weight (mg) in 20.0 mL of the Sample solution |
Dibasic Calcium Phosphate Dihydrate | IMPURITIES/Heavy Metals, Method I <231> | USP35–NF30 | 2463 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of Test preparation: Change Warm 1.3 g with 3 mL of 3 N hydrochloric acid to completely dissolve. to: Warm 1.3 g with 3 mL of 3 N hydrochloric acid until no more dissolves. |
Anhydrous Dibasic Calcium Phosphate | ASSAY | USP35–NF30 | 2464 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | In line 14 of Analysis: Change W = Sample weight (mg) to: W = Sample weight (mg) in 20.0 mL of the Sample solution |
Anhydrous Dibasic Calcium Phosphate | IMPURITIES/Heavy Metals, Method I <231> | USP35–NF30 | 2464 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of Test preparation: Change Warm 1.3 g with 3 mL of 3 N hydrochloric acid to completely dissolve. to: Warm 1.3 g with 3 mL of 3 N hydrochloric acid until no more dissolves. |
Cod Liver Oil | ASSAY/Vitamin D | USP35–NF30 | 2756 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of Aqueous potassium hydroxide solution: Change Dissolve 800 mg of potassium hydroxide in 1000 mL of freshly boiled water, mix, and cool. to: Dissolve 800 g of potassium hydroxide in 1000 mL of freshly boiled water, mix, and cool. |
Glimepiride Tablets | PERFORMANCE TESTS/Dissolution/Test 1 | USP35–NF30 | 3335 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 3 of Analysis: Change
Result = (rU/rS) × (CS/L) × V × 100 to: Result = (rU/rS) × (CS/L) × V × D x 100 AND after Line 8 of Analysis:… Read More |
Moxifloxacin Ophthalmic Solution | Related compounds/Test 1 | USP35–NF30 | 3960 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 4 of Chromatographic system: Delete The flow rate is about 0.5 mL per minute. |
Metronidazole | ASSAY | USP36–NF31 | 4352 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 8 of Chromatogaphic system: Add new subsection after Injection volume: Run time: Twice the retention time of metronidazole |
Tramadol Hydrochloride Tablets | IMPURITIES/Organic Impurities/Procedure | USP35–NF30 | 4905 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 5 of Analysis: Change Result = (rU/rS) × (CS/CU) × (1/F) × 0.1 to: Result = (rU/rS) × (CS/CU) × (1/F) × 100 |
Triclosan | Related compounds | USP35–NF30 | 4939 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of Procedure: Change Inject a volume (about 0.5 µL) to: Inject a volume (about 2.0 µL) |
Compound Undecylenic Acid Ointment | Assay for zinc undecylenate | USP35–NF30 | 4978 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 17 of Procedure: Change AU, AH, and AL to: AU, AS1, and AS2 |
<660> Containers—Glass | SPECIFIC TESTS/Hydrolytic Resistance/Method | First Supplement to USP35–NF30 | 5150 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | In the Note in line 11 of Titration: Change Rinse the grains by swirling with three 15-mL portions of Purified Water, and add the washings to the main solution. to: Rinse the grains by swirling with three 15-mL portions of Carbon Dioxide-Free Water, and add the washings to the main… Read More |
Esomeprazole Magnesium Delayed-Release Capsules | ASSAY/Procedure | First Supplement to USP35–NF30 | 5473 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of Standard solution: Change Transfer 10 mg of USP Omeprazole RS to a 250-mL volumetric flask, and dissolve in about 10 mL of methanol. to: Transfer 10 mg of USP Omeprazole RS to a 250-mL volumetric flask, and dissolve in about 10 mL of alcohol. |
Esomeprazole Magnesium Delayed-Release Capsules | PERFORMANCE TESTS/Dissolution <711> | First Supplement to USP35–NF30 | 5473 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Change Buffer, Diluent, Mobile phase, System suitability, and Chromatographic system: Proceed as directed in the Assay. to: Buffer, Mobile phase, System suitability, and Chromatographic system: Proceed as directed in the Assay. |
Esterified Estrogens Tablets | ASSAY/Procedure | First Supplement to USP35–NF30 | 5485 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 3 of Analysis: Change Separately calculate the percentage of the labeled amount of sodium estrone sulfate and sodium equilin sulfate in the portion of Conjugated Estrogens taken: to: Separately calculate the percentage of the labeled amount of sodium estrone sulfate and… Read More |
Itraconazole | IMPURITIES/Organic Impurities | First Supplement to USP35–NF30 | 5508 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 1 of Standard solution: Change 1.0 µg/mL of USP Itraconazole RS in Diluent to: 10.0 µg/mL of USP Itraconazole RS in Diluent |
Omega-3-Acid Ethyl Esters Capsules | SPECIFIC TESTS/Microbial Enumeration <61> | First Supplement to USP35–NF30 | 5524 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 2: Change 103 to: 103 cfu/g AND Line 3: Change 102 to: 102 cfu/g |
Carisoprodol Tablets | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP35–NF30 | 5921 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 5: At end of USP Reference Standards, add USP Meprobamate RS |
Cefepime Hydrochloride | IMPURITIES/Organic Impurities/Procedure 1: Limit of N-Methylpyrrolidine | Second Supplement to USP35–NF30 | 5923 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 5 of Chromatographic system: Change Column: 4.0-mm x 25-cm; 5-µm packing L##1 to: Column: 4.0-mm x 25-cm; 5-µm packing L76 AND Delete corresponding footnote: "Available as Metrosep C4-250." |
Cefepime for Injection | IMPURITIES/Organic Impurities/Procedure 1: Limit of N-Methylpyrrolidine | Second Supplement to USP35–NF30 | 5925 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 5 of Chromatographic system: Change Column: 4.0-mm x 25-cm; 5-µm packing L##1 to: Column: 4.0-mm x 25-cm; 5-µm packing L76 AND Delete corresponding footnote: Available as Metrosep C4-250. |
DESCRIPTION AND SOLUBILITY | Ethylcellulose Dispersion Type B | USP35–NF30 | 1118 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Lines 3 and 4: Change
in toluene, in chloroform, and in ethyl acetate; insoluble in water, in glycerin, and in propylene glycol. to: in tetrahydrofuran, and in ethyl acetate; insoluble in water and in chloroform. |
BENTONITE | IDENTIFICATION/A. X-Ray Diffraction <941> | USP35–NF30 | 1705 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 4 of Acceptance criteria: Change
from the pattern of Sample B is 1.492 and 1.504 Å. to: from the pattern of Sample B is between 1.492 and 1.504 Å. |
TRIBASIC CALCIUM PHOSPHATE | IDENTIFICATION/Test A | USP35–NF30 | 1719 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 1 of the Sample solution: Change
Dissolve 100 mg in 5 mL of diluted nitric acid. to: A solution in a slight excess of nitric acid |
CALCIUM SULFATE | ASSAY/Procedure | USP35–NF30 | 1724 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 5 of Titrimetric system: Delete the subsection Blank: 100 mL of water and 4 mL of 3 N hydrochloric acid AND Line 11 of Analysis: Delete the sentence Perform a blank determination. AND Line 13 of Analysis: Change Result = [(V − B… Read More |
MICROCRYSTALLINE CELLULOSE | IDENTIFICATION/B. Procedure | USP35–NF30 | 1746 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | 4th formula of Analysis: Change
Result = (95) × [η]c/WS × [(100 − %LOD)/100] to: Result = [(95) × [η]c]/{WS × [(100 − %LOD)/100]} |
MAGNESIUM STEARATE | IMPURITIES/Chloride and Sulfate, Sulfate <221> | USP35–NF30 | 1847 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 3: Change
0.020 N sulfuric acid (1.0%) to: 0.020 M sulfuric acid (1.0%) |
METHYL ALCOHOL | ASSAY/Procedure | USP35–NF30 | 1865 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 9 of System suitability: Change
Tailing factor: NLT 1.5 for methyl alcohol, System suitability solution to: Tailing factor: NMT 1.5 for methyl alcohol, System suitability solution |
POLYETHYLENE OXIDE | IMPURITIES/Organic Impurities/Procedure: Limit of Free Ethylene Oxide | USP35–NF30 | 1906 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 2 of System suitability: Change
Samples: Standard stock solution and Standard solution C to: Sample: Standard solution C |